Stephan Christgau
Managing Partner @ EIR Ventures
Copenhagen, Denmark
Stephan Christgau is a seed investor at EIR Ventures in Copenhagen focused on Biotechnology and Health Care. Stephan joined Novo A/S in September 2007 as Investment Director of Novo Seeds.Stephan obtained his MSc degree from the Technical University of Denmark in 1988 and his PhD degree in 1992 from the Technical University of Denmark, for a project in diabetes immunology, conducted at Hagedorn Research Institute and University of California, SanFrancisco.Prior to joining Novo Seeds, Stephan was Executive Vice President and Chief Operating Officer at Osteologix where he played a leading role in the development of the company, taking the lead candidate drug through all stages from lead identification to Phase II testing for osteoporosis treatment. He also played an active role in the company’s financing including a public listing in the USA on the OTC exchange through a reverse merger with a public shell company. Previously Stephan has worked in the metabolic bone disease and arthritis areas in Nordic Bioscience and Osteometer Biotech and as a protein chemist in Novo Nordisk A/S.Stephan serves on the Board of Directors of Adenium Biotech ApS, Aros Pharma ApS, Galecto Biotech AB, Inagen ApS, Pcovery ApS and Thrombologic ApS. He also serves as chairman for VentureCup, a non-profit entrepreneurship organization.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Stephan Christgau invests in
Stages Stephan Christgau invests in
Countries Stephan Christgau invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (67%)
- Health Care 2 (33%)
- Biopharma 1 (17%)
- Biometrics 1 (17%)
- Life Science 1 (17%)
Stage
- Seed 2 (33%)
- Series A 2 (33%)
- Series C 1 (17%)
- Series D 1 (17%)
Country
- Denmark 3 (50%)
- The Netherlands 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Henlez uses precise enzymes to create disruptive topical treatments for recurrent follicular skin problems. The company can be reached via mail, phone, or physical address. | $988.4K / Seed / Oct 24, 2022 | ||
| Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection. The company's immunotoxin is highly effective, potent and fast-acting that kills lytic and latently infected cells, enabling patients to have long-term health benefits for transplantation. | $32M / Series A / Jun 08, 2022 | ||
| Scenic Biotech is a developer of a genomics and immunotherapy technologies created to unlock genetic suppressors as a new class of drug targets.The company's immunotherapy technologies tackle diseases on the genetic level and focuses on disease suppressing genes., it uses genomics to develop innovative therapies for patients affected by severediseases. | $31M / Series A / Mar 09, 2022 | ||
| Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection. The company's immunotoxin is highly effective, potent and fast-acting that kills lytic and latently infected cells, enabling patients to have long-term health benefits for transplantation. | Seed / Sep 29, 2020 | ||
| Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medicalneed. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. | $64M / Series D / Sep 25, 2020 | ||
| Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medicalneed. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. | $90.2M / Series C / Oct 26, 2018 |
Co-Investors
About EIR Ventures
EIR Ventures is a new Life Science Venture Group in the Nordics.
EIR Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andreas Segerros
Founding Partner
|
|||
Lene Gerlach
Partner
|
|||
|
Stephan Christgau
Managing Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Stephan Christgau invest in?
Stephan Christgau invests primarily in Biotechnology, Health Care and Biopharma startups, most often at Seed and Series A stage. Most of the 6 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Stephan Christgau?
Public channels for Stephan Christgau include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Stephan Christgau last invest?
The most recent investment recorded for Stephan Christgau closed in Oct 2022. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
